CBD Life Sciences Inc.
CBDL · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $16 | $12 | $15 | $39 |
| % Growth | 38% | -23.9% | -61.2% | – |
| Cost of Goods Sold | $29 | $7 | $26 | $23 |
| Gross Profit | -$13 | $5 | -$11 | $16 |
| % Margin | -78.3% | 39.6% | -71.6% | 40.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $25 | $346 | $285 | $83 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$37 | -$37 | $0 |
| Operating Expenses | $25 | $309 | $248 | $83 |
| Operating Income | -$38 | -$342 | -$296 | -$67 |
| % Margin | -234.9% | -2,948% | -1,941.7% | -172.1% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$38 | -$342 | -$296 | -$67 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$38 | -$342 | -$296 | -$67 |
| % Margin | -234.9% | -2,948% | -1,941.8% | -172.1% |
| EPS | 0 | -0 | -0 | -0 |
| % Growth | 100% | 0% | 0% | – |
| EPS Diluted | 0 | -0 | -0 | -0 |
| Weighted Avg Shares Out | 3,413,972 | 3,097,305 | 2,062,527 | 641,701 |
| Weighted Avg Shares Out Dil | 3,413,972 | 3,097,305 | 2,062,527 | 641,701 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $19 | $0 | $19 | $19 |
| EBITDA | -$19 | -$342 | -$277 | -$49 |
| % Margin | -119.1% | -2,948% | -1,820.1% | -124.9% |